Selskapet har i samråd med sin revisor besluttet å foreta presiseringer i årsregnskapet. Selskapet ønsker å innarbeide en bedre beskrivelse av selskapets utvikling, og mer informative forutsetninger rundt impairmenttest. Det vil derfor bli utarbeidet nytt årsregnskap der det antas å ikke innebære endringer i årsresultat
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Recommended Reading
-
Hofseth BioCare ASA ("HBC" or the "Company") today announces the appointment of Leif Arne Giske as new Chief Financial Officer (CFO) of the HBC Group, effective immediately. Mr. Giske has been with...
Read More -
HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down...
Read More